Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Measles, mumps and rubella

Infectious diseases, microbiology and sexual health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Suspected measles in healthcare

Fever, cough, coryza, conjunctivitis and a descending maculopapular rash may expose susceptible patients and staff before laboratory confirmation, with severe risk in pregnancy and immune suppression.

Action: Move the patient away from shared air immediately, use airborne infection precautions, notify the proper officer or health protection team on suspicion, and coordinate urgent testing and contact risk assessment.

Synopsis

Recognise three notifiable viral infections, isolate suspected measles immediately, protect vulnerable contacts and pregnancy, and use the current UK immunisation schedule accurately.

  • Measles causes high fever, cough, coryza and conjunctivitis followed by Koplik spots and a blanching rash that begins on the face or hairline and spreads downwards.
  • Isolate suspected measles from shared air and notify the health protection team immediately on clinical suspicion; do not wait for oral-fluid confirmation.
  • MMR-containing vaccine within 72 hours of measles exposure can protect eligible susceptible contacts; selected vulnerable contacts may need human normal immunoglobulin as soon as possible and up to six days.
  • Mumps usually causes painful unilateral or bilateral parotid swelling, but orchitis, aseptic meningitis, pancreatitis and hearing loss can dominate the presentation.
  • Rubella is often mild, with low fever, fine rash, posterior auricular or suboccipital lymphadenopathy and adult arthralgia, yet maternal infection can cause congenital rubella syndrome.
  • MMR and MMRV are live vaccines and are contraindicated during pregnancy and substantial immune suppression; vaccinate susceptible patients after pregnancy when safe.
  • Children born on or after 1 January 2025 are offered routine MMRV at 12 and 18 months in England; transitional cohorts and catch-up follow their date-of-birth schedule.
  • There is no routine specific antiviral for uncomplicated measles, mumps or rubella: care is supportive while infection control, complication treatment and prevention remain decisive.

Key red flags

Suspected measles in a waiting room, ward or emergency department requires immediate airborne isolation and public-health notification before test confirmation.

Hypoxia, respiratory distress, dehydration, encephalopathy, seizure or focal neurology during measles requires hospital assessment for pneumonitis, bacterial complication or encephalitis.

Mumps with severe headache, neck stiffness, altered consciousness, testicular pain, abdominal pain or hearing change suggests meningitis, orchitis, pancreatitis or sensorineural injury.

Any suspected rubella illness or exposure during pregnancy needs same-day obstetric, virology and health-protection assessment because congenital risk depends on gestation and true maternal infection.

A rash illness in a substantially immunosuppressed person may be atypical, prolonged and severe, so absence of classic morphology does not safely exclude measles or rubella.

An infant, pregnant contact or severely immunosuppressed contact exposed to measles needs urgent health-protection risk assessment while post-exposure prophylaxis remains possible.

Measles prodrome

High fever with cough, coryza, red watery eyes and malaise precedes the rash; tiny white Koplik spots may appear on the buccal mucosa.

Measles exanthem

A blanching erythematous maculopapular rash begins behind the ears or at the hairline, spreads down the trunk and limbs and may become confluent.

Investigation priorities

01
Immediate clinical and exposure assessmentFirst step

Identify probable measles and vulnerable contacts before laboratory confirmation.

Management branches

MEASLESIsolate and notify first

Fever with cough, coryza, conjunctivitis or a descending rash creates clinical suspicion of measles.

  1. Keep the patient out of common waiting space, place them in an appropriate airborne isolation room and use respiratory protective equipment under local infection-control policy.
  2. Notify the proper officer or health protection team immediately, recording rash onset, vaccination, travel, exposure, pregnancy, immune status and places attended while infectious.
  3. Obtain oral-fluid and any rapid PCR samples advised by UKHSA without sending the patient through shared clinical areas or delaying treatment of complications.
  4. Assess oxygenation, hydration and neurology, admit severe disease safely, and treat bacterial superinfection or organ failure while providing supportive measles care.

Key medicines

MMRV vaccine for the routine childhood programmePaediatric programme dose: give 0.5 mL of the supplied live MMRV vaccine by the authorised subcutaneous or intramuscular route; children born from 1 January 2025 receive routine doses at 12 and 18 months.Confirm the date-of-birth pathway, product information, live-vaccine contraindications, pregnancy and substantial immunosuppression; programme transitions mean not every child receives the same ages or number of MMRV doses.
MMR vaccine for older catch-up and measles exposureGive 0.5 mL of an authorised live MMR vaccine by the product-approved route; use two valid doses at least four weeks apart for susceptible older children or adults, and give eligible measles PEP within 72 hours.Do not give during pregnancy or substantial immune suppression; assess previous severe component allergy, defer when clinically appropriate, and advise avoiding pregnancy for one month after vaccination.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • National measles guidelines
  • Measles: the green book chapter
  • Mumps: the green book chapter
  • Rubella: the green book chapter
  • Introduction of a routine varicella (MMRV) vaccination programme for children at one year and at 18 months
  • Administration of HNIG for measles post-exposure prophylaxis

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting review
Mumps complications

Testicular pain and swelling, meningism, encephalopathy, upper abdominal pain or hearing loss can occur with or without prominent parotitis.

Congenital rubella syndrome

Sensorineural deafness, cataract or pigmentary retinopathy, patent ductus arteriosus, growth restriction and developmental impairment indicate fetal infection.

JurisdictionUnited Kingdom